{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.0","upperLimit":"28.3","value":"21.7"},{"groupId":"OG001","lowerLimit":"23.3","upperLimit":"32.5","value":"27.7"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"Disease control rate (DCR) is defined as the proportion of participants with best response of complete response (CR), partial response (PR), or stable disease (SD) of ≥ 12 weeks duration","dispersionType":"95% Confidence Interval","groups":[{"description":"Tremelimumab 10mg/kg","id":"OG000","title":"TREMELIMUMAB"},{"description":"Placebo.","id":"OG001","title":"PLACEBO"}],"paramType":"NUMBER","populationDescription":"ITT population","reportingStatus":"POSTED","timeFrame":"Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.","title":"Disease Control Rate by Treatment Arm","type":"SECONDARY","typeUnitsAnalyzed":"Participants","unitOfMeasure":"Percentage"}